During the past decade, Tower Hematology Oncology Medical Group conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 6 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tower Hematology Oncology Medical Group" #1 sponsor was "Pfizer" with 11 trials, followed by "Genzyme, a Sanofi Company" with 3 trials sponsored, "Cambridge Antibody Technology" with 2 trials sponsored, "Favrille" with 2 trials sponsored and "SCRI Development Innovations, LLC" with 2 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tower Hematology Oncology Medical Group" #1 collaborator was "Aventis Pharmaceuticals" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Emmaus Medical, Inc." with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Tower Hematology Oncology Medical Group" are "Colorectal Cancer" (3 trials), "Lung Cancer" (3 trials), "Prostate Cancer" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials) and "Gaucher Disease, Type 1" (2 trials). Many other conditions were trialed in "Tower Hematology Oncology Medical Group" in a lesser frequency.

Most popular intervention types in "Tower Hematology Oncology Medical Group" are "Drug" (35 trials), "Biological" (4 trials), "Other" (3 trials), "Radiation" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Docetaxel" (3 trials), "Gemcitabine" (3 trials), "5-fluorouracil" (2 trials) and "Biological therapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Tower Hematology Oncology Medical Group" are 38 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Tower Hematology Oncology Medical Group". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Tower Hematology Oncology Medical Group, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tower Hematology Oncology Medical Group, 10 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".